Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cholecystokinin 2 Receptor Agonist 177Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma: Results of the Lumed Phase 0a Study.
Rottenburger C, Nicolas GP, McDougall L, Kaul F, Cachovan M, Vija AH, Schibli R, Geistlich S, Schumann A, Rau T, Glatz K, Behe M, Christ ER, Wild D. Rottenburger C, et al. Among authors: geistlich s. J Nucl Med. 2020 Apr;61(4):520-526. doi: 10.2967/jnumed.119.233031. Epub 2019 Sep 13. J Nucl Med. 2020. PMID: 31519804 Free PMC article. Clinical Trial.
Targeting of the Cholecystokinin-2 Receptor with the Minigastrin Analog 177Lu-DOTA-PP-F11N: Does the Use of Protease Inhibitors Further Improve In Vivo Distribution?
Sauter AW, Mansi R, Hassiepen U, Muller L, Panigada T, Wiehr S, Wild AM, Geistlich S, Béhé M, Rottenburger C, Wild D, Fani M. Sauter AW, et al. Among authors: geistlich s. J Nucl Med. 2019 Mar;60(3):393-399. doi: 10.2967/jnumed.118.207845. Epub 2018 Jul 12. J Nucl Med. 2019. PMID: 30002107 Free article.
Targeted Radiotherapeutics from 'Bench-to-Bedside'.
Müller C, Béhé M, Geistlich S, van der Meulen NP, Schibli R. Müller C, et al. Among authors: geistlich s. Chimia (Aarau). 2020 Dec 23;74(12):939-945. doi: 10.2533/chimia.2020.939. Chimia (Aarau). 2020. PMID: 33357286 Free article. Review.
First-in-human administration of terbium-161-labelled somatostatin receptor subtype 2 antagonist ([161Tb]Tb-DOTA-LM3) in a patient with a metastatic neuroendocrine tumour of the ileum.
Fricke J, Westerbergh F, McDougall L, Favaretto C, Christ E, Nicolas GP, Geistlich S, Borgna F, Fani M, Bernhardt P, van der Meulen NP, Müller C, Schibli R, Wild D. Fricke J, et al. Among authors: geistlich s. Eur J Nucl Med Mol Imaging. 2024 Jul;51(8):2517-2519. doi: 10.1007/s00259-024-06641-w. Epub 2024 Mar 7. Eur J Nucl Med Mol Imaging. 2024. PMID: 38448550 Free PMC article. No abstract available.
In-vivo inhibition of neutral endopeptidase 1 results in higher absorbed tumor doses of [177Lu]Lu-PP-F11N in humans: the lumed phase 0b study.
Rottenburger C, Hentschel M, Fürstner M, McDougall L, Kottoros D, Kaul F, Mansi R, Fani M, Vija AH, Schibli R, Geistlich S, Behe M, Christ ER, Wild D. Rottenburger C, et al. Among authors: geistlich s. EJNMMI Res. 2024 Apr 6;14(1):37. doi: 10.1186/s13550-024-01101-w. EJNMMI Res. 2024. PMID: 38581480 Free PMC article.
First-in-human administration of [161Tb]Tb-SibuDAB and comparative dosimetry with standard [177Lu]Lu-PSMA-I&T as part of the PROGNOSTICS phase Ia study.
Chirindel A, Nicolas GP, Westerbergh F, McDougall L, Schmid DE, Geistlich S, Tschan VJ, Busslinger SD, Fokkema A, Aceto N, Bernhardt P, van der Meulen NP, Müller C, Wild D, Schibli R. Chirindel A, et al. Among authors: geistlich s. Eur J Nucl Med Mol Imaging. 2024 Dec 5. doi: 10.1007/s00259-024-07009-w. Online ahead of print. Eur J Nucl Med Mol Imaging. 2024. PMID: 39633183 No abstract available.
13 results